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Advances in molecular tools to characterize the
microbiome have led to the discovery of unique roles
for microbes in human disease. Findings that the
female genital microbiome can influence HIV
acquisition and prevention emphasize the importance
of microbiome analysis in clinical trials that assess the
efficacy of HIV prevention interventions.Genital inflammation and HIV acquisition riskPartial HIV protection demonstrated by the
CAPRISA 004 vaginal microbicide
Globally, more than 90% of HIV is transmitted following
heterosexual sex. Young women in sub-Saharan Africa rep-
resent a key target population for the development of new
methods for HIV prevention, given that HIV prevalence is
significantly higher in this population compared with young
men [1]. In the absence of a vaccine or cure for HIV, em-
phasis has been placed on developing other biomedical
tools that women can use to prevent HIV infection, such as
vaginal microbicides, oral pre-exposure prophylaxis (PrEP),
and better treatments for sexually transmitted infections.
The Centre for the AIDS Programme of Research in South
Africa (CAPRISA) 004 study was a double-blind, random-
ized, placebo-controlled trial conducted in KwaZulu-Natal,
South Africa, which demonstrated that a single vaginal ap-
plication of a microbicide gel containing the antiretroviral
(ARV) tenofovir within 12 h before, and then after sex, re-
duced HIV acquisition by 39% overall, and by 54% in
women with high levels of gel adherence [2]. Although
poor adherence diminished drug efficacy in this and later* Correspondence: lenine.liebenberg@caprisa.org; dkwon@mgh.harvard.edu
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inflammation [3] and the genital microbiome [4] as key bio-
logical factors that contributed to the efficacy of the gel.
Thus, a deeper understanding of the causes of genital
inflammation and the underlying mechanisms by which
vaginal bacteria might lead to reduced efficacy of ARV-
based strategies for PrEP is needed to produce effective
HIV prevention modalities.During sexual transmission of HIV, productive infection
is facilitated by micro-abrasions in the mucosal barrier
and access to local activated CD4+ T cells (HIV target
cells). Genital cytokine biomarkers of inflammation have
been associated with both the number of local target
cells and the potential to compromise the ability of the
genital mucosa to serve as an effective barrier to HIV
infection [5]. The combined effect of genital inflamma-
tion on mucosal barrier integrity and HIV target cell
numbers likely contributes to the association of genital
inflammation and infection by less-infectious HIV
variants [6]. Recent findings have suggested that vaginal
bacteria could be an important underlying contributor
to baseline inflammation and HIV risk in women living
in sub-Saharan Africa.The vaginal microbiome and HIV risk
Increasing evidence suggests that microbial communities
in the female genital tract could directly impact genital
inflammation and HIV acquisition risk. A study by Gos-
mann et al. [7] showed that young South African women
with diverse vaginal microbial communities and low
Lactobacillus abundance acquired HIV at over four-fold
higher rates than those with L. crispatus dominance.
Diverse vaginal microbial communities were closely
associated with elevated genital inflammatory cytokines
and cervical HIV target cells, which probably contrib-
uted to increased susceptibility to HIV. Furthermore,le is distributed under the terms of the Creative Commons Attribution 4.0
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Lactobacillus-dominant vaginal communities [8], whereas
the majority of South African women were found to have
low Lactobacillus abundance without clinical indication of
bacterial vaginosis, which highlights the importance of
geography in defining what constitutes a ‘normal’ vaginal
environment. Furthermore, behavioral, genetic and envir-
onmental factors are also likely to impact the effect of the
vaginal microbiome on HIV risk. For example, the use of
vaginal products for hygiene or for dry vaginal secretions to
increase sexual pleasure has been reported to be common
in several sub-Saharan African countries. These products
might cause changes in vaginal pH and the microbiome,
lead to increased inflammation, and disrupt the vaginal–
epithelial barrier, which could impact HIV risk and micro-
bicide efficacy in women [9].
A role for Lactobacillus dominance in improving
the efficacy of vaginal tenofovir gel
Recent findings by Klatt et al. [4] demonstrate that the va-
ginal microbiome can modulate the efficacy of topical
tenofovir and suggests a novel mechanism for this rela-
tionship. Klatt et al. [4] utilized a metaproteomics ap-
proach to classify the host–microbial proteome of
cervicovaginal lavage specimens from CAPRISA 004 par-
ticipants. The authors identified two major bacterial com-
munities based on relative microbial abundance: a
Lactobacillus-dominant community, and a diverse, non-
Lactobacillus-dominant community. Notably, the authors
demonstrated that, in women with a Lactobacillus-
dominant community, the risk of HIV acquisition was re-
duced by 61% using the tenofovir gel, whereas no signifi-
cant HIV protection was observed in those with a vaginal
microbiome dominated by non-Lactobacillus species. Fur-
thermore, Klatt et al. [4] observed higher levels of genital
tenofovir in women with Lactobacillus dominance than
those who had non-Lactobacillus dominance, and attrib-
uted this to metabolism of tenofovir by Gardnerella vagi-
nalis present in those with non-Lactobacillus-dominant
communities. However, these observations might apply
specifically to topical tenofovir-based microbicides, as bac-
terial vaginosis-associated bacteria appear to have no im-
pact on the ability of oral tenofovir to protect women
from HIV acquisition [10]. Future work is needed to better
understand the specific bacterial community functions
that potentially enable ARV metabolism. Additionally, a
closer examination of the mechanism of host sensing of
vaginal bacterial communities that lead to increased HIV
acquisition risk might help identify novel targets to reduce
this risk.
Future considerations
Research on the relationship between the genital micro-
biome and HIV risk has raised several key considerationsfor future investigations. Klatt et al. [4] combined the
use of proteomics and genomics platforms to classify va-
ginal bacterial communities in the absence of clinical
measures of bacterial vaginosis such as the Nugent
score. Despite good concordance between the proteomic
footprint and 16S rRNA gene sequence data for some
bacterial taxa, 16S rRNA analysis revealed diversity in
the Lactobacillus-dominant group that the proteomics
data could not resolve, which raises concerns about
whether these approaches are adequate at this time to
fully unravel the complexities of vaginal microbial com-
munities. Further annotation of proteomic databases for
the specific purposes of bacterial identification will help
improve this approach and enable the simultaneous
identification of downstream bacterial effectors. Comple-
mentary methodologies such as host single-cell tran-
scriptomics, microbial metagenomics, and metabolomics
will help assess the impact of the vaginal microbiome on
genital inflammation, HIV risk, and PrEP efficacy. The
Klatt et al. study [4] identified an in vitro impact of spe-
cific bacteria on drug metabolism, but the contribution
in the context of a community of bacteria in the vagina
is less established – as is the effect of various bacterial
products on the mucosal environment. A further oppor-
tunity for investigation is longitudinal analysis of vaginal
bacterial community dynamics, particularly given the in-
fluence of the menstrual cycle, endogenous hormones,
hormonal contraceptives, and vaginal insertive practices.
Recent studies on the vaginal microbiome highlight
the complexities of host–microbial interactions in the fe-
male genital tract and underscore the need for a deeper
understanding of the interplay between the microbiome,
host immune responses and bacterial metabolic func-
tion, and its impact on HIV acquisition risk. It will be
important to understand whether the vaginal micro-
biome can be used to identify individuals at high risk of
HIV acquisition or PrEP failure so that more-intensive
measures to reduce risk can be taken. Ultimately, a
deeper understanding of the vaginal microbiome might
provide an opportunity to manipulate these communi-
ties to create durable alterations that decrease HIV
acquisition risk, particularly in vulnerable women living
in sub-Saharan Africa.
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